XPOVIO is the first and only FDA-approved oral XPO1 inhibitor that gets to the cell’s nucleus, which leads to cell cycle arrest and apoptosis in cancer cells¹

**INDICATION**
- XPOVIO® (selinexor) is a prescription medicine approved in combination with bortezomib and dexamethasone (XVd) to treat adult patients with multiple myeloma who have received at least one prior therapy.

**SELECTED SAFETY INFORMATION**
- The most common ARs (≥20%) were fatigue, nausea, decreased appetite, diarrhea, peripheral neuropathy, upper respiratory tract infection, decreased weight, cataract, and vomiting.
- Grade 3-4 laboratory abnormalities (≥10%) were thrombocytopenia, lymphopenia, hypophosphatemia, anemia, hyponatremia and neutropenia.
- The treatment discontinuation rate due to ARs was 19%; 64% of patients had a reduction in the XPOVIO dose, and 83% had the dose of XPOVIO interrupted.

Please see full Prescribing Information at XPOVIOpro.com.

**REFERENCES:**
1. XPOVIO (selinexor) [prescribing information]. Newton, MA: Karyopharm Therapeutics Inc.; April 2021.